Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia

Mary L. Marnach, Kristina A. Butler, Michael R. Henry, Catherine E. Hutz, Carrie L. Langstraat, Christine M. Lohse, Petra Marcela Casey

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Limited therapeutic guidelines exist regarding medical therapy, ideal dosing, duration of therapy, or recommendations for timing of endometrial reassessment for women with endometrial intraepithelial neoplasia (EIN) who desire fertility preservation or who are not optimal surgical candidates. We aimed to determine the effectiveness of oral progestogens (OP) versus the levonorgestrel-releasing intrauterine system (LNG IUS) in the medical treatment of EIN. Methods: We retrospectively identified women with EIN at our institution from 2007 through 2014 and compared the outcomes of those treated with OP versus LNG IUS. Results: Among 390 women, 296 were initially treated with OP and 94 with LNG IUS. Baseline characteristics of the patient groups were comparable, except for higher median body mass index in the LNG IUS group versus the OP group (37 kg/m2 vs. 31 kg/m2; p < 0.001). Among 332 women with follow-up endometrial biopsies (263 OP and 69 LNG IUS), EIN subcategory 1 (benign endometrial hyperplasia) resolved in 83% and 87% of patients, respectively (p = 0.31). Rates of resolution of EIN subcategory 2 (endometrial intraepithelial neoplasia) were also similar between groups (68% vs. 62%; p = 0.82). In women with EIN subcategory 3 (endometrial adenocarcinoma), 22% of those using LNG IUS and one of two women treated with OP had resolution of disease as of last follow-up. Conclusions: OP and LNG IUS offer similar endometrial protection for women with EIN. LNG IUS offers convenience, minimal adverse effects, reversibility, and long-term endometrial protection.

Original languageEnglish (US)
Pages (from-to)368-373
Number of pages6
JournalJournal of Women's Health
Volume26
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Levonorgestrel
Progestins
Neoplasms
Therapeutics
Fertility Preservation
Endometrial Hyperplasia
Adenocarcinoma
Body Mass Index
Guidelines
Biopsy

Keywords

  • Endometrial adenocarcinoma
  • endometrial hyperplasia
  • endometrial intraepithelial neoplasia
  • levonorgestrel-releasing intrauterine system
  • oral progestogens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia. / Marnach, Mary L.; Butler, Kristina A.; Henry, Michael R.; Hutz, Catherine E.; Langstraat, Carrie L.; Lohse, Christine M.; Casey, Petra Marcela.

In: Journal of Women's Health, Vol. 26, No. 4, 01.04.2017, p. 368-373.

Research output: Contribution to journalArticle

Marnach, Mary L. ; Butler, Kristina A. ; Henry, Michael R. ; Hutz, Catherine E. ; Langstraat, Carrie L. ; Lohse, Christine M. ; Casey, Petra Marcela. / Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia. In: Journal of Women's Health. 2017 ; Vol. 26, No. 4. pp. 368-373.
@article{c4b4175f56be4c79b71759b7cdd454ee,
title = "Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia",
abstract = "Background: Limited therapeutic guidelines exist regarding medical therapy, ideal dosing, duration of therapy, or recommendations for timing of endometrial reassessment for women with endometrial intraepithelial neoplasia (EIN) who desire fertility preservation or who are not optimal surgical candidates. We aimed to determine the effectiveness of oral progestogens (OP) versus the levonorgestrel-releasing intrauterine system (LNG IUS) in the medical treatment of EIN. Methods: We retrospectively identified women with EIN at our institution from 2007 through 2014 and compared the outcomes of those treated with OP versus LNG IUS. Results: Among 390 women, 296 were initially treated with OP and 94 with LNG IUS. Baseline characteristics of the patient groups were comparable, except for higher median body mass index in the LNG IUS group versus the OP group (37 kg/m2 vs. 31 kg/m2; p < 0.001). Among 332 women with follow-up endometrial biopsies (263 OP and 69 LNG IUS), EIN subcategory 1 (benign endometrial hyperplasia) resolved in 83{\%} and 87{\%} of patients, respectively (p = 0.31). Rates of resolution of EIN subcategory 2 (endometrial intraepithelial neoplasia) were also similar between groups (68{\%} vs. 62{\%}; p = 0.82). In women with EIN subcategory 3 (endometrial adenocarcinoma), 22{\%} of those using LNG IUS and one of two women treated with OP had resolution of disease as of last follow-up. Conclusions: OP and LNG IUS offer similar endometrial protection for women with EIN. LNG IUS offers convenience, minimal adverse effects, reversibility, and long-term endometrial protection.",
keywords = "Endometrial adenocarcinoma, endometrial hyperplasia, endometrial intraepithelial neoplasia, levonorgestrel-releasing intrauterine system, oral progestogens",
author = "Marnach, {Mary L.} and Butler, {Kristina A.} and Henry, {Michael R.} and Hutz, {Catherine E.} and Langstraat, {Carrie L.} and Lohse, {Christine M.} and Casey, {Petra Marcela}",
year = "2017",
month = "4",
day = "1",
doi = "10.1089/jwh.2016.5774",
language = "English (US)",
volume = "26",
pages = "368--373",
journal = "Journal of women's health (2002)",
issn = "1540-9996",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia

AU - Marnach, Mary L.

AU - Butler, Kristina A.

AU - Henry, Michael R.

AU - Hutz, Catherine E.

AU - Langstraat, Carrie L.

AU - Lohse, Christine M.

AU - Casey, Petra Marcela

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background: Limited therapeutic guidelines exist regarding medical therapy, ideal dosing, duration of therapy, or recommendations for timing of endometrial reassessment for women with endometrial intraepithelial neoplasia (EIN) who desire fertility preservation or who are not optimal surgical candidates. We aimed to determine the effectiveness of oral progestogens (OP) versus the levonorgestrel-releasing intrauterine system (LNG IUS) in the medical treatment of EIN. Methods: We retrospectively identified women with EIN at our institution from 2007 through 2014 and compared the outcomes of those treated with OP versus LNG IUS. Results: Among 390 women, 296 were initially treated with OP and 94 with LNG IUS. Baseline characteristics of the patient groups were comparable, except for higher median body mass index in the LNG IUS group versus the OP group (37 kg/m2 vs. 31 kg/m2; p < 0.001). Among 332 women with follow-up endometrial biopsies (263 OP and 69 LNG IUS), EIN subcategory 1 (benign endometrial hyperplasia) resolved in 83% and 87% of patients, respectively (p = 0.31). Rates of resolution of EIN subcategory 2 (endometrial intraepithelial neoplasia) were also similar between groups (68% vs. 62%; p = 0.82). In women with EIN subcategory 3 (endometrial adenocarcinoma), 22% of those using LNG IUS and one of two women treated with OP had resolution of disease as of last follow-up. Conclusions: OP and LNG IUS offer similar endometrial protection for women with EIN. LNG IUS offers convenience, minimal adverse effects, reversibility, and long-term endometrial protection.

AB - Background: Limited therapeutic guidelines exist regarding medical therapy, ideal dosing, duration of therapy, or recommendations for timing of endometrial reassessment for women with endometrial intraepithelial neoplasia (EIN) who desire fertility preservation or who are not optimal surgical candidates. We aimed to determine the effectiveness of oral progestogens (OP) versus the levonorgestrel-releasing intrauterine system (LNG IUS) in the medical treatment of EIN. Methods: We retrospectively identified women with EIN at our institution from 2007 through 2014 and compared the outcomes of those treated with OP versus LNG IUS. Results: Among 390 women, 296 were initially treated with OP and 94 with LNG IUS. Baseline characteristics of the patient groups were comparable, except for higher median body mass index in the LNG IUS group versus the OP group (37 kg/m2 vs. 31 kg/m2; p < 0.001). Among 332 women with follow-up endometrial biopsies (263 OP and 69 LNG IUS), EIN subcategory 1 (benign endometrial hyperplasia) resolved in 83% and 87% of patients, respectively (p = 0.31). Rates of resolution of EIN subcategory 2 (endometrial intraepithelial neoplasia) were also similar between groups (68% vs. 62%; p = 0.82). In women with EIN subcategory 3 (endometrial adenocarcinoma), 22% of those using LNG IUS and one of two women treated with OP had resolution of disease as of last follow-up. Conclusions: OP and LNG IUS offer similar endometrial protection for women with EIN. LNG IUS offers convenience, minimal adverse effects, reversibility, and long-term endometrial protection.

KW - Endometrial adenocarcinoma

KW - endometrial hyperplasia

KW - endometrial intraepithelial neoplasia

KW - levonorgestrel-releasing intrauterine system

KW - oral progestogens

UR - http://www.scopus.com/inward/record.url?scp=85018491569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018491569&partnerID=8YFLogxK

U2 - 10.1089/jwh.2016.5774

DO - 10.1089/jwh.2016.5774

M3 - Article

C2 - 27901412

AN - SCOPUS:85018491569

VL - 26

SP - 368

EP - 373

JO - Journal of women's health (2002)

JF - Journal of women's health (2002)

SN - 1540-9996

IS - 4

ER -